Protein Binding in Antiretroviral Therapies

No abstract is available for this paper.

• Publication year

  2003

• Venue

  AIDS Research and Human Retroviruses

• Publication date

  2003-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/088922203769232629PMID 14585213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

  2004cited by this paper
• Therapeutic drug monitoring in HIV infection: current status and future directions

  2002cited by this paper
• Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.

  2002cited by this paper
• Changes in plasma protein binding have little clinical relevance

  2002cited by this paper
• The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

  2002cited by this paper
• Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens.

  2002cited by this paper
• Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios.

  2001cited by this paper
• Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.

  2001cited by this paper
• Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

  2001cited by this paper
• Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.

  2001cited by this paper
• Indinavir plasma protein binding in HIV-1-infected adults

  2000cited by this paper
• Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.

  2000cited by this paper
• Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

  2000cited by this paper
• Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

  2000cited by this paper
• Kinetics of Antiviral Activity and Intracellular Pharmacokinetics of Human Immunodeficiency Virus Type 1 Protease Inhibitors in Tissue Culture

  1999cited by this paper
• Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

  1998cited by this paper
• Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant.

  1998cited by this paper
• Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

  1997cited by this paper
• Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.

  1996cited by this paper
• Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease

  1996cited by this paper
• Plasma protein binding displacement interactions--why are they still regarded as clinically important?

  1994cited by this paper
• Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV)

  1993cited by this paper
• Occurrence of HIV-1 and HIV-2 in Brazil.

  1992cited by this paper
• Clinical pharmacokinetics: Concepts and applications (2nd edn.)

  1989cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Repair of mucosal damage induced by ethanol in the rat stomach. Effects of concentration, exposure period and prostaglandins.

  1988cited by this paper
• Drug binding to human alpha-1-acid glycoprotein in health and disease.

  1988cited by this paper
• Plasma protein binding of drugs: some basic and clinical aspects

  1987cited by this paper
• Protein Binding and Drug Clearance

  1984cited by this paper
• Alpha 1 -acid glycoprotein and binding of basic drugs.

  1983cited by this paper
• Alpha 1 -acid glycoprotein and binding of basic drugs.

  1983cited by this paper
• Pharmacokinetics of theophylline in neonates.

  1981cited by this paper
• Disease-induced Changes in the Plasma Binding of Basic Drugs

  1980cited by this paper
• Protein Binding and Kinetics of Drugs in Liver Diseases

  1977cited by this paper
• A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.

  1976cited by this paper

• Protein-Linker Co-engineering for Broad-Spectrum Antiviral Development against Enveloped Viruses.

  2026cites this paper
• Dolutegravir with enteral feeds in intensive care: Case series with therapeutic drug monitoring

  2025cites this paper
• Critical Care Pharmacology of Antiretroviral Therapy in Adults

  2025influential citation
• Formulation and characterization of a fixed-dose microemulsion containing efavirenz, emtricitabine, and tenofovir

  2025cites this paper
• Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women

  2024cites this paper
• ART-DEX: A novel strategy to monitor broadly neutralizing antibody activity during antiretroviral therapy of HIV-1

  2024cites this paper
• The Association of Intraocular Efavirenz Concentrations and HIV-1 Viral Load Among Persons With HIV

  2024influential citation
• Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions

  2024cites this paper
• Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines

  2024cites this paper
• Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention

  2023cites this paper
• Pharmacokinetic of Tecovirimat in subjects with Mpox.

  2023cites this paper
• Modeling Antiretrovial Treatment to Mitigate HIV in the Brain: Impact of the Blood-Brain Barrier

  2023cites this paper
• Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.

  2023cites this paper
• Chemical inhibition of DPP9 sensitizes the CARD8 inflammasome in HIV-1-infected cells

  2022cites this paper
• Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs

  2022cites this paper
• Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study

  2022cites this paper
• Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID‐19 Therapeutics

  2021cites this paper
• Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development

  2021cites this paper
• CARD8 inflammasome sensitization through DPP9 inhibition enhances NNRTI-triggered killing of HIV-1-infected cells

  2021cites this paper
• Identification and characterization of novel plasma proteins in drug resistant HIV/AIDS patients by SWATH-MS

  2021cites this paper
• Antiretroviral Penetration and Drug Transporter Concentrations in the Spleens of Three Preclinical Animal Models and Humans

  2020cites this paper
• Clinical utility of monitoring free drug levels

  2020cites this paper
• Mass spectrometric investigations into the brain delivery of abacavir, stavudine and didanosine in a rodent model

  2020cites this paper
• Identification and differential expression of serotransferrin and apolipoprotein A-I in the plasma of HIV-1 patients treated with first-line antiretroviral therapy

  2020cites this paper
• Reply to the letter to the Editor “Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts”

  2020cites this paper
• Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study

  2020cites this paper
• HIV-1 Sanctuary Sites—the Role of Membrane-Associated Drug Transporters and Drug Metabolic Enzymes

  2020cites this paper
• Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development

  2020cites this paper
• Comparing ultrafiltration and equilibrium dialysis to measure unbound plasma dolutegravir concentrations based on a design of experiment approach

  2020cites this paper
• Drug interactions are not always predictable: the curious case of valproic acid and dolutegravir and a possible explanation.

  2019cites this paper
• Mass Spectrometry Imaging Demonstrates the Regional Brain Distribution Patterns of Three First-Line Antiretroviral Drugs

  2019cites this paper
• Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species

  2019cites this paper
• Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach

  2019cites this paper
• Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.

  2019cites this paper
• The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis

  2019cites this paper
• Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

  2019cites this paper
• Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions

  2018cites this paper
• Lipid based delivery of Efavirenz: An answer to its erratic absorption and food effect

  2018cites this paper
• Spectroscopic and molecular docking studies of the binding of the angiotensin II receptor blockers (ARBs) azilsartan, eprosartan and olmesartan to bovine serum albumin

  2018cites this paper
• Unraveling the binding characteristics of the anti-HIV agents abacavir, efavirenz and emtricitabine to bovine serum albumin using spectroscopic and molecular simulation approaches

  2018cites this paper
• Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes

  2018cites this paper
• Treatment of HIV associated neurocognitive disorders

  2018cites this paper
• Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species

  2018influential citation
• Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion

  2018cites this paper
• Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus‐infected pregnant women

  2018cites this paper
• Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

  2018cites this paper
• CNS penetration of ART in HIV-infected children

  2018cites this paper
• Keeping an eye on the brain of perinatally HIV-infected children

  2017cites this paper
• Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study

  2017cites this paper
• Current Progress in the Pharmacogenetics of Infectious Disease Therapy

  2017cites this paper
• Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients

  2017cites this paper
• An oral formulation of efavirenz‐loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile

  2017cites this paper
• Inflammation and pharmacokinetics: potential implications for HIV-infection

  2017influential citation
• MULTISPECIES EVALUATION OF ANTIRETROVIRAL DISPOSITION IN A PUTATIVE TISSUE RESERVOIR OF HIV: IMPLICATIONS FOR ERADICATION

  2017cites this paper
• Physiological scaling factors and mechanistic models for prediction of renal clearance from in vitro data

  2016cites this paper
• Monitoring Free Drug Concentration: Clinical Usefulness and Analytical Challenges

  2016cites this paper
• Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

  2016cites this paper
• Efavirenz Self-Nano-Emulsifying Drug Delivery System: In Vitro and In Vivo Evaluation

  2016cites this paper
• Problems and Proceedings to Antiretroviral Therapy for the Treatment of AIDS

  2016cites this paper
• Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients

  2016cites this paper
• Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital

  2016cites this paper
• Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24

  2016cites this paper
• Nutritional status of HIV-infected patients during the first year HAART in two West African cohorts

  2015cites this paper
• Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

  2015cites this paper
• Pharmacokinetics of antiretrovirals in mucosal tissue

  2015cites this paper
• A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography–Mass Spectrometry

  2015cites this paper
• Method Development and Validation for Quantitative Determination of Para Chloroaniline, an Impurity, in Efavirenz Active Pharmaceutical Ingredient by Liquid Chromatography - Electrospray Ionization - Mass Spectrometry/Mass Spectrometry

  2015cites this paper
• Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies

  2015cites this paper
• Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines.

  2015cites this paper
• Central Nervous System Penetration of Antiretroviral Drugs: Pharmacokinetic, Pharmacodynamic and Pharmacogenomic Considerations

  2015cites this paper
• Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti –tuberculosis therapy

  2014influential citation
• Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations

  2014cites this paper
• Integrated approach to structure-based enzymatic drug design: molecular modeling, spectroscopy, and experimental bioactivity.

  2014cites this paper
• Therapeutic drug monitoring of intracellular anti-infective agents.

  2014cites this paper
• Preclinical safety evaluation.

  2014cites this paper
• Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography-tandem mass spectrometry and ultrafiltration methods.

  2014cites this paper
• Rational use of plasma protein and tissue binding data in drug design.

  2014cites this paper
• Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention

  2014cites this paper
• Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect

  2013cites this paper
• Etravirine in CSF is highly protein bound.

  2013cites this paper
• Correction: HIV Protease Inhibitors Do Not Cause the Accumulation of Prelamin A in PBMCs from Patients Receiving First Line Therapy: The ANRS EP45 “Aging” Study

  2013cites this paper
• Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy: Implications for Treatment Guidelines

  2013cites this paper
• EVASION OF EFFLUX AND ENHANCING BIOAVAILABILITY OF AMPRENAVIR BY PRODRUG DERIVATIZATION

  2013influential citation
• Dynamical models of biomarkers and clinical progression for personalized medicine: the HIV context.

  2013cites this paper
• Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.

  2013cites this paper
• Evaluation of the Effect of Cobicistat on the In Vitro Renal Transport and Cytotoxicity Potential of Tenofovir

  2013cites this paper
• Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (B

  2013cites this paper
• Protein-Free Efavirenz Concentrations in Cerebrospinal Fluid and Blood Plasma Are Equivalent: Applying the Law of Mass Action To Predict Protein-Free Drug Concentration

  2013cites this paper
• Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents

  2013cites this paper
• Plasma protein binding: from discovery to development.

  2013cites this paper
• Effect of blood protein concentrations on drug-dosing regimes: practical guidance

  2013cites this paper
• HIV and Interferon Regulatory Factor 1: A Story of Manipulation and Control

  2013cites this paper
• Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue

  2013cites this paper
• In Vitro and In Vivo Activities of AIC292, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor

  2013cites this paper
• Review of Drug Interactions with Telaprevir and Antiretrovirals

  2013cites this paper
• Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

  2013cites this paper
• Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

  2012cites this paper
• Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women

  2012cites this paper
• Safety and Pharmacokinetics of Nelfinavir During the Second and Third Trimesters of Pregnancy and Postpartum

  2012cites this paper
• Drug-drug interactions between antiretrovirals and fluconazole in HIV-infected patients

  2012cites this paper